The function and mechanism of COX-2 in angiogenesis of gastric cancer cells
- Liping Yao†1,
- Fei Liu†1,
- Liu Hong†1,
- Li Sun1,
- Shuhui Liang1,
- Kaichun Wu1Email author and
- Daiming Fan1Email author
© Yao et al; licensee BioMed Central Ltd. 2011
Received: 20 June 2010
Accepted: 25 January 2011
Published: 25 January 2011
Here we aimed to investigate the effect of COX-2 siRNA on proliferation and angiogenesis of gastric cancer cells.
The gastric cancer cell line SGC7901 was transfected with COX-2 siRNA, then the growth and angiogenesis of cells were detected by in vitro and in vivo assay. Human microarray, RT-PCR and western blot were used to identify differentially expressed angiogenesis-related molecules in cells with decreased expression of COX-2.
Down-regulation of COX-2 could significantly inhibit the in vitro and in vivo growth of gastric cancer cells, and suppress the migration and tube formation of human umbilical vein endothelial cells. Totally 23 angiogenesis-related molecules were found involved in COX-2-induced angiogenesis suppression. The results of RT-PCR and western blot showed that down-regulation of COX-2 might inhibit VEGF, Flt-1, Flk-1/KDR, angiopoietin-1, tie-2, MMP2 and OPN.
COX-2 might mediate tumor angiogenesis and growth, and could be considered as a target for gastric cancer therapy.
Gastric cancer is the second leading cause of cancer associated death in the world, particularly in Asian countries. The treatment outcome of this common malignancy is still not satisfactory and various chemotherapeutic attempts in an adjuvant setting have failed to improve the survival rate in gastric cancer. Recently, angiogenesis has been found related to hematogenous recurrence and poor prognosis in gastric cancer . Angiogenesis is the growth of new vessels from existing vasculature. A balance of angiogenic and angiostatic growth factors tightly controls physiological angiogenesis. Tipping of this balance towards a pro-angiogenic environment is termed the 'angiogenic switch' and occurs in situations such as tissue hypoxia, inflammation or neoplasia .
COX-2, a COX isoenzyme catalyzing the production of prostaglandins, has been observed in most gastric cancer tissues compared with the accompanying normal mucosa. Studies in different cancers have suggested a relationship between COX-2 and increased pro-angiogenic growth factors, in particular VEGF . COX-2 is thought to promote angiogenesis and so drive the malignant phenotype. Overexpression of COX-2 might contribute to angiogenesis of gastric cancer . However, the potential mechanism underlying the role of COX-2 in angiogenesis remains unclear.
Here we have demonstrated novel observations that COX-2 might play important roles in angiogenesis of gastric cancer through regulation of VEGF, Flt-1, Flk-1/KDR, angiopoietin-1, tie-2, MMP2 and OPN.
Human gastric cancer cell line SGC7901 was cultivated in Dulbecco's modified Eagle's medium supplemented with 10% heat-inactivated fetal calf serum, penicillin (100 U/ml) and streptomycin (100 μg/ml), in a CO2 incubator (Forma Scientific) . Human umbilical vein endothelial cells (HUVEC-12; ATCC, Manassas, VA) were grown in Kaighn's modification of Ham's F12 medium (ATCC) with 2 mM Lglutamine, 1.5 g/l sodium bicarbonate, 0.1 mg/ml heparin, 0.03 mg/ml endothelial cell growth supplement and 10% FBS.
Plasmid construction and transfection
The siRNA oligos for COX-2 were designed according to previous report. Target sequences were aligned to the human genome database in a BLAST search to ensure that the choosing sequences were not highly homologous with other genes. For oligo-1, S: 5'-tttgcatcgatgtcaccatagaacatctatggtgacatcgatgcttttt-3', AS: 5'-ctagaaaaagcatcgatgtcacc atagatgttctatggtgacatcgatg-3' For annealing to form DNA duplexes, 100 μM of each S and AS oligos was used. The duplexes were diluted and then ligated with mU6pro vector which previously digested by the Bbs I/Xba I restriction enzyme and gel purified at room temperature for 30 min. The products were transformed into DH5α competent cells. Ampicillin-resistant colonies were chosen, identified by restriction digestion and further confirmed by DNA sequencing.
SGC7901 cells were planted in six-well plates and cultured in drug-free medium. At 90-95% confluence, cells were washed twice with PBS, grew in 2 ml of DMEM without antibiotics. Using Lipofectamine™ 2000 reagent (Invitrogen, Inc. Carlsbad CA), 2 μg of mU6pro-COX-2siRNA plasmids were transfected into cells according to the manufacturer's instructions. The cells transfected with mU6pro vector alone were served as negative control. Forty-eight hours later, cells were placed in growth medium containing G418 (GIBCO) for clone selection. The expression levels of COX-2 in G418-resistant clones were evaluated by western blot analysis.
All of the PCR products were separated on ethidium bromide stained agarose, and visualized with UV as described previously .
Western blot analysis
The western blot was done as described previously. In brief, total cellular proteins were prepared and then quantified by Bradford method . A measure of 80 ug of lysates were electrophoresed in 12% SDS-PAGE and blotted on a nitrocellulose membrane (Immoblin-P, Millipore, Bedford, MA, USA). Membranes were blocked with 5% fat-free milk powder at room temperature and incubated overnight with antibody at 4°C. After three washes for 15 min in PBS-T, the membrane was incubated with the HRP-conjugated goat anti-mouse IgG antibody (Wuhan, Hubei, China) for 1 h at room temperature. The enhanced chemiluminescence (Amersham Life Science, Piscataway, NJ, USA) was added and monitored for the development of color.
Cell growth assay
Cells were seeded on a 96-well plate at 3 × 104 cells/well. Each sample had four replicates. The medium was replaced at 2-day intervals. Viable cells were counted by the 3-[4,5-dimethylthiazol-2-yl]- 2,5-diphenyltetrazolium bromide (MTT) assay after 2, 4, 6, and 8 days.
Tumor growth in nude mice
Female athymic nu/nu mice, 5-6 weeks of age, were obtained from FMMU Experimental Animal Co. (Shaanxi, China) and housed in a pathogen-free facility for all of the experiments. The logarithmically growing cells were trypsinized and resuspended in D'Hanks solution, and 5 × 106 cells in 0.2 ml were injected subcutaneously into the left flank of mice . Experimental and control groups had at least 6 mice each. Tumors were measured twice weekly with microcalipers, and the tumor volume was calculated according to the formula: volume = length × (width2)/2.
Quantification of tumor microvessel density
Tumor microvessel densities (MVD) were quantified by anti-CD31 immunohistochemistry. Briefly, tumor sections from nude mice were cut using a LEICA cryostat and the paraffin sections were mounted on positively charged Superfrost slides and dried overnight. The immunostaining was done according to standardized protocols.
Tube formation assay
Tube formation assay was performed as described previously (Chia et al, 2010). Briefly, Confluent HUVEC cells were harvested and diluted in DMEM with 10% FBS, which were then seeded on Matrigel-coated 24-well plates. Cell culture medium was then replaced by conditioned medium. After 16 h, Matrigel was fixed, stained with H & E and examined under inverted microscope. The mean tube length in five random fields per well was quantified by computer software.
Cell migration assay
Briefly, confluent monolayer of HUVEC was cultured with non-growth factor containing media for 12 h before harvesting. Harvested cells were suspended in serum-free DMEM199 and HUVEC cells were seeded onto tissue culture inserts in triplicate. The inserts were removed after 8 h culture and washed with PBS. Non-migrated cells on the upper surface of the inserts were removed by wiping with cotton swabs. The inserts were fixed in neutral buffered formalin solution, stained with hematoxylin and eosin (H & E) and mounted on microscope slides. HUVEC migration was quantitated by counting the number of cells in three random fields (!200) per insert.
cDNA microarray analysis
The gene expression was compared between SGC7901-siRNA and SGC7901-vector cells for three times . RNA was extracted from 80-90% confluent cells using Trizol and purified with RNeasy spin columns (Qiagen, Valencia, CA) according to the manufacturers' instructions. Quality of the RNA was ensured before labeling by analyzing 20 to 50 ng of each sample using the RNA 6000 NanoAssay and a Bioanalyzer 2100 (Agilent, Palo Alto, CA). Samples with a peak ratio of 1.8 to 2.0 were considered suitable for labeling. Cy3- or Cy5-labeled cDNA was generated and the Cy3/Cy5 single-stranded cDNA/cot1 DNA pellet was resuspended in hybridization buffer, then the hybridization mix was applied to GEArray Q Series Human Angiogenesis Gene Array. The ratios of gene expression were considered to be significant if they were 2 or 0.5 in at least two independent experiments. Genes were assigned to functional families based on information from LocusLink and PubMed.
Data were presented as mean ± standard deviation (S.D.) unless otherwise specified. Comparisons between groups were made using the Student-Newman-Keuls test or the Kruskal-Wallis test. All data were analyzed using the SPSS software package (SPSS Inc, Chicago, USA). A value of P < 0.05 was considered significant.
Down-regulation of COX-2 inhibited the growth and tumorigenecity of gastric cancer cells
Down-regulation of COX-2 inhibited angiogenesis of gastric cancer cells
Effect of COX-2 on angiogenesis related molecules
Angiogenesis is an essential process required for the growth and metastatic ability of solid tumors. Tumor angiogenesis is the proliferation of a network of blood vessels penetrating into the cancerous growths to supply nutrients and oxygen and remove metabolic waste products from tumors. Tumor angiogenesis is a complex process and involves the tight interplay of tumor cells, endothelial cells, phagocytes and their secreted factors, which may act as promoters or inhibitors of angiogenesis . More than a dozen different proteins (such as VEGF, bFGF, IL8, etc.), as well as several smaller molecules (such as adenosine, PGE, etc.) have been identified as angiogenic factors secreted by tumor cells to mediate angiogenesis [11, 12].
Lines of evidence suggest that COX-2 is involved in the steps of gastric carcinogenesis. Increased expression of COX-2 was frequently found in gastric cancer, in which COX-2 expression is correlated with poor prognostic outcome. Up-regulation of cox-2 expression and activity in the ulcer base not only during the acute phase of inflammation but also in the ulcer healing stage and especially in areas of intense tissue repair . It has been found that cyclooxygenase-2 inhibitors have antiproliferative and antiangiogenic activity in several types of human cancer. However, the mechanism of COX-2 in angiogenesis remains unclear.
In this study, the data showed that down-regulation of COX-2 could significantly inhibit the in vitro and in vivo growth of gastric cancer cell line SGC7901, and suppress the migration and tube formation of human umbilical vein endothelial cells, which was consistent with previous report. To our knowledge, we have firstly identified a expression pattern of angiogenesis-related molecules in COX-2-mediated angiogenesis. The results of RT-PCR and western blot showed that down-regulation of COX-2 might inhibit VEGF, Flt-1, KDR, angiopoietin-1, tie-2, MMP2 and OPN.
In conclusion, COX-2 might mediate tumor angiogenesis and growth, and could be considered as a target for gastric cancer therapy. It was becoming increasingly clear that the signals that govern angiogenesis, functioned in complex regulatory networks rather than simple linear pathways, and that these networks might be wired differently in different cells or tumor types. The precise mechanism by which COX-2 brought about these changes, and which of these changes were primary or secondary ones, remained to be elucidated.
This study was supported in part by grants from the National Scientific Foundation of China (30873005, 30801142, 30770958 and 30871141).
- Liu W, Zhang X, Sun W: Developments in treatment of esophageal/gastric cancer. Curr Treat Options Oncol. 2008, 9 (4-6): 375-87. 10.1007/s11864-009-0097-1.View ArticlePubMedGoogle Scholar
- Wagner AD, Moehler M: Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era. Curr Opin Oncol. 2009, 21: 381-5. 10.1097/CCO.0b013e32832c42e0.View ArticlePubMedGoogle Scholar
- Wu K, Nie Y, Guo C, Chen Y, Ding J, Fan D: Molecular basis of therapeutic approaches to gastric cancer. J Gastroenterol Hepatol. 2009, 24 (1): 37-41. 10.1111/j.1440-1746.2008.05753.x.View ArticlePubMedGoogle Scholar
- Mrena J, Wiksten JP, Kokkola A, Nordling S, Ristimäki A, Haglund C: COX-2 is associated with proliferation and apoptosis markers and serves as an independent prognostic factor in gastric cancer. Tumour Biol. 2010, 31 (1): 1-7. 10.1007/s13277-009-0001-4.View ArticlePubMedGoogle Scholar
- Hong L, Zhao Y, Han Y, Guo W, Jin H, Qiao T, Che Z, Fan D: Mechanisms of growth arrest by zinc ribbon domain-containing 1 in gastric cancer cells. Carcinogenesis. 2007, 28 (8): 1622-8. 10.1093/carcin/bgm064.View ArticlePubMedGoogle Scholar
- Hong L, Wang J, Zhao Y, Han Z, Zhou X, Guo W, Zhang X, Jin H, Wu K, Ding J, Fan D: DARPP-32 mediates multidrug resistance of gastric cancer through regulation of P-gp and ZNRD1. Cancer Invest. 2007, 25 (8): 699-705. 10.1080/07357900701566304.View ArticlePubMedGoogle Scholar
- Han Z, Hong L, Han Y, Wu K, Han S, Shen H, Li C, Yao L, Qiao T, Fan D: Phospho Akt mediates multidrug resistance of gastric cancer cells through regulation of P-gp, Bcl-2 and Bax. J Exp Clin Cancer Res. 2007, 26 (2): 261-8.PubMedGoogle Scholar
- Hong L, Piao Y, Han Y, Wang J, Zhang X, Du Y, Cao S, Qiao T, Chen Z, Fan D: Zinc ribbon domain-containing 1 (ZNRD1) mediates multidrug resistance of leukemia cells through regulation of P-glycoprotein and Bcl-2. Mol Cancer Ther. 2005, 4 (12): 1936-42. 10.1158/1535-7163.MCT-05-0182.View ArticlePubMedGoogle Scholar
- Hong L, Han Y, Zhang H, Li M, Gong T, Sun L, Wu K, Zhao Q, Fan D: The prognostic and chemotherapeutic value of miR-296 in esophageal squamous cell carcinoma. Ann Surg. 2010, 251 (6): 1056-63. 10.1097/SLA.0b013e3181dd4ea9.View ArticlePubMedGoogle Scholar
- Chia JS, Du JL, Hsu WB, Sun A, Chiang CP, Wang WB: Inhibition of metastasis, angiogenesis, and tumor growth by Chinese herbal cocktail Tien-Hsien Liquid. BMC Cancer. 2010, 10 (1): 175-10.1186/1471-2407-10-175.PubMed CentralView ArticlePubMedGoogle Scholar
- Cao Y: Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseases. Nat Rev Drug Discov. 2010, 9 (2): 107-15. 10.1038/nrd3055.View ArticlePubMedGoogle Scholar
- Elewa HF, El-Remessy AB, Somanath PR, Fagan SC: Diverse effects of statins on angiogenesis: new therapeutic avenues. Pharmacotherapy. 2010, 30 (2): 169-76. 10.1592/phco.30.2.169.View ArticlePubMedGoogle Scholar
- Na rdone G, Rocco A: Chemoprevention of gastric cancer: role of COX-2 inhibitors and other agents. Dig Dis. 2004, 22 (4): 320-6. 10.1159/000083593.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.